UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES
EXCHANGE ACT OF 1934
For
the month of November 2026
Commission
File Number 001-40517
BON
NATURAL LIFE LIMITED
(Translation
of registrant’s name into English)
Room
601, Block C, Gazelle Valley, No.69, Jinye Road
High-Tech
Zone, Xi’an, Shaanxi, China
People’s
Republic of China
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form
40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report
to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that
the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to
be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the
subject of a Form 6-K submission or other Commission filing on EDGAR.
Attached
hereto and incorporated herein is the Registrant’s press release issued on November 20, 2026, titled “BON Unveils Joint Lab
for Natural Ingredients & Biomanufacturing with China Oat Group, Advancing Life Sciences Innovation.”
Exhibits
The
following exhibit is included in this Form 6-K:
| Exhibit
No. |
|
Description
of Exhibit |
| 99.1 |
|
Press release titled “BON Unveils Joint Lab for Natural Ingredients & Biomanufacturing with China Oat Group, Advancing Life Sciences Innovation.” |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| Date:
November 20, 2026 |
Bon
Natural Life Limited |
| |
|
|
| |
By: |
/s/
Yongwei Hu |
| |
|
Yongwei
Hu |
| |
|
Chairman
and Chief Executive Officer |
Exhibit
99.1
BON Unveils Joint Lab for Natural Ingredients & Biomanufacturing with China Oat Group, Advancing Life Sciences Innovation
XIAN,
China, Nov. 20, 2026 /PRNewswire/ — Bon Natural Life Limited (NASDAQ: BON) (“BON” or the “Company”), a
leading provider of bio-ingredient solutions for the natural, health, and personal care industries, today announced that its subsidiary,
Xi’an App-Chem Bio (Tech) Co., Ltd. (“App-Chem”) recently convened a symposium with China Oat Group Co., Ltd. (“China
Oat Group”) on the theme of “Advancing the High-Quality Development of China’s Health Industry”. At the event,
the two parties announced the establishment of the BON Natural Ingredients and Biomanufacturing Joint Laboratory (the “BON Joint
Lab” or the “Joint Lab”).
Through
an innovative collaboration model, the BON Joint Lab aims to build an integrated innovation framework spanning the entire value chain,
from fundamental research and pilot-scale development to standard-setting and industrial commercialization. The Joint Lab will focus
on developing an AI-driven technological platform for the biomanufacturing of natural ingredients, with synthetic biology serving as
its technological foundation and artificial intelligence (AI) as a key competitive differentiator. Its primary focus will be the development
of biomanufacturing technologies for high-value natural ingredients. This integrated technological framework is expected to enhance the
Joint Lab’s competitive position in the natural ingredients biomanufacturing sector while offering the industry new alternatives
to conventional production methods.
Oats
are widely recognized for their nutritional value and health benefits. They contain bioactive compounds such as beta-glucan and avenanthramides
(AVAs), which have demonstrated various biological activities, including cardiovascular protection, blood glucose regulation, antioxidant
effects, and anti-inflammatory properties. As a supplier of oat-based health products, China Oat Group serves a market characterized
by strong demand and significant growth potential. However, limited availability of natural raw materials and high sourcing costs have
constrained the broader commercial application and market expansion of oat-derived products.
Through
the establishment of the Joint Lab, BON and China Oat Group aim to develop biomanufacturing technologies for oat-derived natural ingredients,
with the goal of fundamentally addressing challenges related to supply availability, supply stability, and high production costs. BON
and China Oat Group believe that this initiative is of significant importance in expanding the market for oat-derived natural ingredients.
Standards
development plays a critical role in the biomanufacturing of natural ingredients. The unique complexity of natural ingredient sourcing,
heightened regulatory scrutiny of product safety, and distinct consumer preferences for naturally derived ingredients make the establishment
of standards for biomanufactured natural ingredients critically important to their commercial value.
BON
and China Oat Group have undertaken extensive and productive work in developing quality standards for natural ingredients. The Joint
Lab will make standards development a dedicated area of focus, conducting systematic testing and validation of key parameters, including
ingredient purity, safety, and elemental and isotopic profiles. Through a comprehensive and integrated process of evaluation and optimization,
the Joint Lab aims to establish systematic differentiation in product standards across multiple dimensions, including safety, differentiated
quality standards, and similarity to naturally derived counterparts.
BON
has established a strong presence in the natural ingredients biomanufacturing sector and has articulated its vision of becoming an “AI-driven
pioneer in digital nutrition”. The Company is committed to accelerating the transition from conventional natural extraction methods
to AI-driven biomanufacturing. The Company believes that it has built a strong technological foundation in natural products, biosynthesis,
and the application of AI in biology, supported by robust industrialization capabilities and global market development expertise.
China
Oat Group has developed extensive expertise across the entire oat value chain and holds more than ten invention patents in China, along
with multiple patents in the United States, Europe, Canada, Australia, and other markets. Leveraging its advanced technologies in areas
such as oat protein enzymatic hydrolysis and the preservation of beta-glucan bioactivity, China Oat Group has developed a portfolio of
oat-based nutritional products whose health benefits have been evaluated through medical research. China Oat Group was also among the
first companies to achieve large-scale, standardized deep processing of oats, with its related technologies receiving authoritative certifications
in Europe and the United States.
Mr.
Yongwei Hu, Chairman of BON, commented, “Our strategic collaboration with China Oat Group marks a pivotal step in our efforts to
establish a stronger presence in the core natural ingredients sector, accelerate our expansion into the rapidly growing global biomanufacturing
market, and further strengthen our position as an innovation leader in the industry. Through the Joint Lab, we aim to advance cutting-edge
research in areas such as the biosynthesis of high-value natural ingredients, the discovery of functional bioactive compounds, and precision
nutrition interventions. We are committed to accelerating the commercialization of scientific and technological innovations and delivering
a broader range of safe and effective health solutions to consumers. Through the disciplined execution of our technology-driven business
strategy, we seek to unlock significant commercial value and generate sustainable returns for our investors.”
About
Bon Natural Life Limited (“BON”)
BON
is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit
the Company’s website at http://www.bnlus.com.
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe
Harbor Statement
This
press release contains certain statements that may include “forward-looking statements.” All statements other than statements
of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified
by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known
and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements
are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not
place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s
actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors,
including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available
on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf
are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume
a duty to update these forward-looking statements.